Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer's failed pursuit of AstraZeneca, that would-be deal has seemingly ignited an inversion deal mania.
Our newest potential coupling is big pharma AbbVie (NYSE: ABBV ) and Ireland-based Shire (NASDAQ: SHPG ) . It's not an obvious fit for AbbVie beyond the immediate tax benefits, but Shire is an ADHD and burgeoning orphan-drug powerhouse growing at a faster rate than its peers.
In this episode of Market Check-Up, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss this new proposed inversion deal, how Shire might respond, and what it means for investors.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.